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This work is based on the hypothesis that intraductal
injection can treat existing lesions and prevent future
breast cancers originating in the epithelial cells lining the
breast ducts. We have previously demonstrated our ability
to access the entire mammary gland through the teat in
mouse and rat mammary tumor models. Further, we
showed that several other common chemotherapeutic
drugs such as 5 fluorouracil, carboplatin, and methotrex-
ate were effective, but not to the same extent as PLD. Thus,
intraductal injection of PLD has potential in the preven-
tion and neo-adjuvant therapy of breast cancer.
Recently, we observed that in addition to rendering the
mammary glands tumor free for more than 3 months after
all of the control animals had developed multiple tumors,
mammary glands of PLD treated mice were stunted in
their growth. Instead of the florid growth with multiple
branches and side branches studded with terminal end
buds, akin to a "spring tree" seen in normal glands the
PLD treated mammary gland presented the aspect of an
"autumn tree". In the transgenic mice, the epithelial cells
in the entire mammary gland express the MMTV-Her2/
neu transgene and at even higher levels during pregnancy.
This raised the concern that stimulation of proliferation of
these cells, for example, by pregnancy, may result in a
higher incidence of spontaneous mammary tumors in the
PLD treated mice.
What then is the response of this treated mammary gland
to a new pregnancy? To test this concept, we induced preg-
nancy in PLD treated mice. Her2/neu mice treated with
intraductal PLD, like their untreated controls, had normal
deliveries, with pups of normal weight and number in the
litter. However, unlike control mice, their pups survived
for less than one week. Long term follow-up showed that
pregnancy did not increase the incidence of tumors in
PLD treated mice. Their mammary glands showed a very
poor proliferative response to the pregnancy hormones
and remained stunted in their growth. It is likely that PLD
not only affected the eradication of preneoplasias but also
resulted in a depletion of normal mammary gland stem
cells This concept is being tested by determining the dif-
ference in stem cell content between untreated and PLD
treated glands by transplantation of serial dilutions of epi-
thelial cells from sham and PLD treated glands into
cleared mouse fat pads, examination of markers of stem
cells, such as ALDHA, etc. If proven to be the case, these
findings raise the possibility that long term protection
may be achieved by intraductal injection of PLD to
women at high risk of developing breast cancer.
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